NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $0.58 -0.04 (-6.43%) (As of 12/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends About Bolt Biotherapeutics Stock (NASDAQ:BOLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$0.57▼$0.6350-Day Range$0.56▼$0.6852-Week Range$0.54▼$1.56Volume241,926 shsAverage Volume164,674 shsMarket Capitalization$22.28 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingHold Company OverviewBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Read More… WaveBot: The Automated Trading Tool for This Bull Market (Ad)The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.Register for the FREE Workshop Now & get $10 in Bitcoin Bolt Biotherapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks62nd Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 491st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bolt Biotherapeutics are expected to grow in the coming year, from ($1.61) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bolt Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.39% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 53.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.39% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 53.64%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentBolt Biotherapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.MarketBeat Follows1 people have added Bolt Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders30.90% of the stock of Bolt Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLT Stock News HeadlinesBolt Biotherapeutics Third Quarter 2024 Earnings: Misses ExpectationsNovember 15, 2024 | finance.yahoo.comBolt Biotherapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.December 5, 2024 | Crypto Swap Profits (Ad)Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer LookNovember 15, 2024 | markets.businessinsider.comBolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue EstimatesNovember 13, 2024 | msn.comBolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | markets.businessinsider.comBolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comBy popular demand, Epiphone brings back the Mike Dirnt and Gene Simmons-approved Grabber BassSeptember 27, 2024 | msn.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $1.12 at the beginning of 2024. Since then, BOLT shares have decreased by 48.0% and is now trading at $0.5822. View the best growth stocks for 2024 here. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.04. The company earned $1.14 million during the quarter, compared to analysts' expectations of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative trailing twelve-month return on equity of 69.46%. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $150 million in an IPO on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO. Who are Bolt Biotherapeutics' major shareholders? Bolt Biotherapeutics' top institutional shareholders include Geode Capital Management LLC (0.92%) and FMR LLC (0.30%). Insiders that own company stock include Holdings A/S Novo, Edgar Engleman, Vivo Capital Viii, Llc and William P Quinn. View institutional ownership trends. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include Athenex (ATNX), NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPeng (XPEV). Company Calendar Last Earnings11/12/2024Today12/04/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CUSIP09769810 CIK354655 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$8.00 Low Stock Price Target$1.00 Potential Upside/Downside+501.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,200,000.00 Net Margins-665.56% Pretax Margin-665.56% Return on Equity-69.46% Return on Assets-48.55% Debt Debt-to-Equity Ratio0.21 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$9.78 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.20Miscellaneous Outstanding Shares38,273,000Free Float26,447,000Market Cap$22.28 million OptionableNot Optionable Beta0.93 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:BOLT) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.